Cybulski et al. [115] analyzed 4008 cases across 13 tumor types and discovered an elevated risk of thyroid, prostate, and breast cancer in carriers of truncating CHEK2 variants [120,122,123,124,125]. Here, CHEK2 is linked to neoplasm.